Mahkam Zanganeh - 26 Mar 2024 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Signature
/s/ Mahkam Zanganeh
Issuer symbol
SMMT
Transactions as of
26 Mar 2024
Net transactions value
+$411,094
Form type
4
Filing time
27 Mar 2024, 20:28:30 UTC
Previous filing
13 Dec 2023
Next filing
24 Jun 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SMMT Common Stock Purchase $96,720 +26,000 +5.3% $3.72 520,814 27 Mar 2024 Direct F1
transaction SMMT Common Stock Purchase $127,674 +34,321 +0.14% $3.72 24,923,800 27 Mar 2024 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F2, F3
transaction SMMT Common Stock Purchase $112,500 +30,000 $3.75 30,000 26 Mar 2024 Immediate family member F3, F4
transaction SMMT Common Stock Purchase $74,200 +20,000 +67% $3.71 50,000 27 Mar 2024 Immediate family member F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.69 to $3.72 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.78 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.68 to $3.75 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.